Dan Williams PhD, CEO at SynaptixBio discusses current approaches to delivering drugs into the central nervous system (CNS), focusing on the specific challenges for key therapies like gene-silencing drugs that aim to treat rare neurological diseases. Almost half of the 8,000 - 10,000 known rare conditions are neurological.
The blood brain barrier (BBB) is the brain's self-defence mechanism, keeping out bacteria and viruses but allowing in